Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination SARS-CoV-2 variants

被引：0

作者：

Garcia-Perez, Javier ^{[1
,2
]}

Borobia, Alberto M. ^{[3
,4
]}

Perez-Olmeda, Mayte ^{[2
,5
]}

Portoles, Antonio ^{[7
]}

Castano, Luis ^{[7
]}

Campins-Arti, Magdalena ^{[8
]}

Bertran, Maria Jesus ^{[9
]}

Bermejo, Mercedes ^{[1
,2
]}

Arribas, Jose Ramon ^{[2
,4
]}

Lopez, Andrea ^{[5
]}

Ascaso-del-Rio, Ana ^{[6
]}

Arana-Arri, Eunate ^{[7
]}

Camps, Inmaculada Fuentes ^{[10
]}

Vilella, Anna ^{[9
]}

Cascajero, Almudena ^{[1
]}

Garcia-Morales, Maria Teresa ^{[11
]}

de la Osa, Maria Castillo ^{[5
]}

Ingidua, Carla Perez ^{[6
]}

Lora, David ^{[11
,12
,13
]}

Jimenez-Santana, Paloma ^{[1
]}

Pino-Rosa, Silvia ^{[5
]}

de la Camara, Agustin Gomez ^{[12
,13
]}

de la Torre-tarazona, Erick ^{[1
]}

Calonge, Esther ^{[2
]}

Cruces, Raquel ^{[1
]}

Belda-Iniesta, Cristo bal ^{[14
]}

Alcami, Jose ^{[1
,2
]}

Frias, Jesus ^{[3
]}

Carcas, Antonio J. ^{[3
]}

Diez-Fuertes, Francisco ^{[1
,2
]}

机构：

[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiologia, Unidad Inmunopatologi SIDA, Majadahonda 28222, Madrid, Spain

[2] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Majadahonda 28222, Madrid, Spain

[3] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Dept Farmacologia & Terapeut,Serv Med Interna,IdiP, Madrid 28046, Spain

[4] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Serv Med Interna,Dept Med,IdiPAZ, Madrid 28046, Spain

[5] Inst Salud Carlos III ISCIII, Lab Serologia, Ctr Nacl Microbiologia, Majadahonda 28222, Madrid, Spain

[6] IdISSC, Serv Farmacologia Clin, Hosp Clin San Carlos, Madrid 28040, Spain

[7] Cruces Univ Hosp, Endo ERN, UPV EHU, CIBERDEM CIBERER,Biobizkaia, Baracaldo 48903, Vizcaya, Spain

[8] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Med Prevent & Epidemiologia, Barcelona 08035, Spain

[9] Hosp Clin Barcelona, Serv Med Prevent & Epidemiologia, Barcelona 08036, Spain

[10] Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Farmacologia Clin, Unidad Soporte Invest Clin, Barcelona 08035, Spain

[11] Spanish Clin Res Network SCReN ISCIII, Madrid 28029, Spain

[12] Inst Invest Sanitaria Hosp Univ 12 octubre, Madrid 28041, Spain

[13] Univ Complutense Madrid, Fac Estudios Estadist, Madrid 28040, Spain

[14] Directorate Inst Salud Carlos III, Madrid 28029, Spain

来源：

ISCIENCE | 2024年 / 27卷 / 09期

关键词：

D O I：

10.1016/j.isci.2024.110728

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

引用

页数：13

共 50 条

[41] Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Timothy A. Bates
Hans C. Leier
Zoe L. Lyski
Savannah K. McBride
Felicity J. Coulter
Jules B. Weinstein
James R. Goodman
Zhengchun Lu
Sarah A. R. Siegel
Peter Sullivan
Matt Strnad
Amanda E. Brunton
David X. Lee
Andrew C. Adey
Benjamin N. Bimber
Brian J. O’Roak
Marcel E. Curlin
William B. Messer
Fikadu G. Tafesse
Nature Communications, 12
[42] Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, Timothy A.
Leier, Hans C.
Lyski, Zoe L.
McBride, Savannah K.
Coulter, Felicity J.
Weinstein, Jules B.
Goodman, James R.
Lu, Zhengchun
Siegel, Sarah A. R.
Sullivan, Peter
Strnad, Matt
Brunton, Amanda E.
Lee, David X.
Adey, Andrew C.
Bimber, Benjamin N.
O'Roak, Brian J.
Curlin, Marcel E.
Messer, William B.
Tafesse, Fikadu G.
NATURE COMMUNICATIONS, 2021, 12 (01)
[43] Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
Yanay, Noa Berar
Freiman, Sarit
Shapira, Ma'anit
Wishahi, Samar
Hamze, Munir
Elhaj, Mohamad
Zaher, Maha
Armaly, Zaher
KIDNEY INTERNATIONAL, 2021, 99 (06) : 1496 - 1498
[44] UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION A Possible Association
Rabinovitch, Tamar
Ben-Arie-Weintrob, Yael
Hareuveni-Blum, Tamar
Shaer, Boaz
Vishnevskia-Dai, Vicktoria
Shulman, Shiri
Newman, Hadas
Biadsy, Muhammad
Masarwa, Dua
Fischer, Naomi
Yovel, Oren
Goldfeather-Ben Zaken, Shalhevet
Habot-Wilner, Zohar
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (12): : 2462 - 2471
[45] Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
Haller, Maria C.
Kaiser, Robert A.
Langthaler, Simon
Brandstetter, Clara
Apfalter, Petra
Kerschner, Heidrun
Cejka, Daniel
TRANSPLANT INTERNATIONAL, 2022, 35
[46] Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis
Wigner-Jeziorska, Paulina
Janik-Karpinska, Edyta
Niwald, Marta
Saluk, Joanna
Miller, Elzbieta
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
[47] Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Steensels, Deborah
Pierlet, Noella
Penders, Joris
Mesotten, Dieter
Heylen, Line
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (15): : 1533 - 1535
[48] Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
Hyeryung Kwon
Taewon Kim
Neurological Sciences, 2022, 43 : 1487 - 1489
[49] Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination
Bonura, Floriana
Genovese, Dario
Amodio, Emanuele
Calamusa, Giuseppe
Sanfilippo, Giuseppa Luisa
Cacioppo, Federica
Giammanco, Giovanni Maurizio
De Grazia, Simona
Ferraro, Donatella
VACCINES, 2022, 10 (06)
[50] Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
Kwon, Hyeryung
Kim, Taewon
NEUROLOGICAL SCIENCES, 2022, 43 (03) : 1487 - 1489

← 1 2 3 4 5 →